OnKure Therapeutics (OKUR) EBIT (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly EBIT came in at -$15.6 million in Q1 2026, up 8.15% YoY from -$14.4 million in Q1 2025, and down 10.55% on a QoQ basis from -$14.1 million in Q4 2025.
OnKure Therapeutics (OKUR) EBIT (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of EBIT data on file, last reported at -$15.6 million in Q1 2026.
- Quarterly EBIT rose 8.15% year-over-year to -$15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.6 million (changed 0.02% YoY) and the FY2025 annual result came in at -$63.0 million, down 15.75% from the prior year.
- EBIT retreated to -$15.6 million in Q1 2026, from -$14.1 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $21.1 million in Q4 2023 to a low of -$21.0 million in Q2 2023.
- A 5-year average of -$13.2 million and a median of -$14.6 million in 2022 frame the typical range for EBIT.
- Annual changes were most pronounced in 2023 — EBIT surged 244.99% — and 2024, when it slumped 188.57%.
- Tracing OKUR's EBIT over 5 years: stood at -$14.6 million in 2022, then surged by 244.99% to $21.1 million in 2023, then tumbled by 188.57% to -$18.7 million in 2024, then rose by 24.46% to -$14.1 million in 2025, then retreated by 10.55% to -$15.6 million in 2026.
- The last three EBIT figures came in at -$15.6 million (Q1 2026), -$14.1 million (Q4 2025), and -$15.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | -16.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.90 Mn |
| Mar 31, 2026 | -15.62 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | -15.50 Mn |
| Jun 30, 2025 | -16.32 Mn |
| Mar 31, 2025 | -17.00 Mn |
| Dec 31, 2024 | -18.70 Mn |
| Sep 30, 2024 | -11.51 Mn |
| Jun 30, 2024 | -14.34 Mn |
| Mar 31, 2024 | -9.83 Mn |
| Dec 31, 2023 | 21.11 Mn |
| Sep 30, 2023 | -20.89 Mn |
| Jun 30, 2023 | -21.04 Mn |
| Mar 31, 2023 | -16.12 Mn |
| Dec 31, 2022 | -14.56 Mn |
| Sep 30, 2022 | -13.84 Mn |
| Jun 30, 2022 | -12.43 Mn |
| Mar 31, 2022 | -13.02 Mn |
| Dec 31, 2021 | -10.62 Mn |
| Sep 30, 2021 | -12.75 Mn |